how glp 1 drugs work GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes Current Insights, Advantages and Challenges

Concerns about the potential association between certain diabetes medications and cardiovascular disease meant that in 2010 the FDA approved liraglutide on condition that Novo Nordisk conduct a post-marketing study to evaluate the drug's effect on the incidence of major cardiovascular events (Nielsen, DeChiaro, Goldman)

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

Miyawaki, K

This multi-targeted approach helps reduce appetite by influencing the pathways involved in regulating food intake and energy expenditure: The hypothalamus receives full signals approximately 4 times longer per meal when taking Zepbound, significantly reducing overall food intake

Liu Z, Zhang M, Zhou T, Shen Q, Qin X